Pharmacokinetics of ketotifen after oral administration to healthy male subjects.
The pharmacokinetics of 2 mg ketotifen from four different oral dosage forms were examined in two randomized, balanced cross-over studies. Forty healthy male subjects participated. Each of 20 subjects received two capsule formulations and each of the other 20 subjects received two syrup formulations. Ketotifen concentrations in plasma were determined by a modified GC-MS method. The limit of quantitation was 40 pg ml-1. Inter-day precision and accuracy calculated from quality control samples were 16.3 per cent (-1.9 per cent), 19.8 per cent (+4.5 per cent) and 23.6 per cent (+5.9 per cent) at plasma concentration levels of 86 (n = 18), 215 (n = 19) and 343 (n = 18) pg ml-1, respectively. Ketotifen was rapidly absorbed from all dosage forms reaching Cmax in the order of 400 pg ml-1 after the syrup formulations and 300 pg ml-1 after the capsule formulations within 2 to 4 h. The syrup formulations showed a significantly more rapid rate of absorption as assessed by Tmax. No significant differences in extent of absorption between dosage forms were observed. The terminal elimination half-life of ketotifen varied between subjects from 7 to 27 hours with a mean of about 12 h. The minor pharmacokinetic difference between dosage forms observed in this study is unlikely to be of clinical significance.
Grahnén
A
A
Pharmaco Medical Consultants (PMC) AB, Uppsala, Sweden.
Lönnebo
A
A
Beck
O
O
Eckernäs
S A
SA
Dahlström
B
B
Lindström
B
B
D000284:Administration, Oral; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D007665:Ketotifen / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008297:Male
D007665:Ketotifen